What is the current stock price of ADMA Biologics, Inc. (ADMA)?

As of the latest market data, ADMA Biologics, Inc. (ADMA) is trading at $8.24. The stock has seen a loss of -2.60% today.

Does ADMA Biologics, Inc. (ADMA) pay a dividend?

Based on current data, ADMA Biologics, Inc. does not have a confirmed active dividend policy.

What is the market cap of ADMA Biologics, Inc.?

The current market capitalization of ADMA Biologics, Inc. (ADMA) is approximately unavailable.

ADMA

ADMA Biologics, Inc.·Healthcare

8.24

2.600%(−0.22)

Market Closed

8.30

0.728%(+0.06)

After Hours

Last Updated: — ET

52W L: $7.2152W H: $22.37

ADMA NEWS

prnewswire.com

7h ago

Rosen Law Firm Encourages ADMA Biologics, Inc. Investors to Inquire About Securities Class Action Investigation - ADMA

NEW YORK, May 23, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of ADMA Biologics, Inc. (NASDAQ: ADMA) resulting from allegations that ADMA Biologics may have issued materially misleading business information to the investing public. So What: If you purchased ADMA Biologics securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

globenewswire.com

20h ago

ADMA Investor News: If You Have Suffered Losses in ADMA Biologics, Inc. (NASDAQ: ADMA), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

NEW YORK, May 22, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of ADMA Biologics, Inc. (NASDAQ: ADMA) resulting from allegations that ADMA Biologics may have issued materially misleading business information to the investing public.

globenewswire.com

23h ago

Lowey Dannenberg, P.C. is Investigating ADMA Biologics (NASDAQ: ADMA) for Potential Violations of the Federal Securities Laws and Encourages Investors with more than $50,000 in Losses to Contact the Firm

NEW YORK, May 22, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating ADMA Biologics (NASDAQ: ADMA) (“ADMA Biologics” or the “Company”) for potential violations of the federal securities laws.

zacks.com

1d ago

Will the IG Market Challenges Affect ADMA Biologics Prospects in 2026?

ADMA cuts 2026 guidance after weak Bivigam sales and IG market pressure weigh on revenues amid rising competition and order volatility.

globenewswire.com

1d ago

ADMA Inquiry News: ADMA Biologics Investors are Notified of BFA Law's Ongoing Investigation into the Company's Potential Misstatements – Contact the Firm if You Lost Money

ADMA Biologics Investors are Notified of BFA Law's Ongoing Investigation into the Company's Potential Misstatements – Contact the Firm if You Lost Money

fool.com

1d ago

Why This Fund Added $12 Million to a Biotech Stock That's Now Down 58% in a Year

ADMA Biologics develops plasma-derived therapies for immune deficiencies and infectious diseases, leveraging a vertically integrated model.

Company Profile

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Sector

Healthcare

Industry

Biotechnology

Employees

685

IPO Date

2013-10-17

Beta

0.82

Websitewww.admabiologics.com↗